Analysis and Commentary STEVEN GROSSMAN 1/4/19 Analysis and Commentary STEVEN GROSSMAN 1/4/19 Can the Alliance Help to End the Shutdown? No and Yes! Read More Advocacy at a Glance STEVEN GROSSMAN 1/4/19 Advocacy at a Glance STEVEN GROSSMAN 1/4/19 Soon To Be Released: Alliance’s FDA Shutdown Toolkit Read More STEVEN GROSSMAN 12/21/18 STEVEN GROSSMAN 12/21/18 What Happens At and After Midnight, Cinderella? Read More Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Barring a Last-Minute Deal, A Partial FDA Shutdown is Likely Read More Analysis and Commentary STEVEN GROSSMAN 12/15/18 Analysis and Commentary STEVEN GROSSMAN 12/15/18 Is a Shutdown on the Horizon? Read More Analysis and Commentary STEVEN GROSSMAN 12/10/18 Analysis and Commentary STEVEN GROSSMAN 12/10/18 Critical Issues for the CVM Moving Forward Read More Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Two-Week CR Extension: Can It End the Impasse? Read More Analysis and Commentary STEVEN GROSSMAN 11/30/18 Analysis and Commentary STEVEN GROSSMAN 11/30/18 "The Best of Times" ... "The Worst of Times" Read More Advocacy at a Glance STEVEN GROSSMAN 11/30/18 Advocacy at a Glance STEVEN GROSSMAN 11/30/18 A Full Year Continuing Resolution: The Biggest Threat to FDA’s FY19 Funding Read More Analysis and Commentary STEVEN GROSSMAN 11/20/18 Analysis and Commentary STEVEN GROSSMAN 11/20/18 Let Us All -- Again -- Give Thanks Read More Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Special Thanksgiving Message Read More Analysis and Commentary STEVEN GROSSMAN 11/9/18 Analysis and Commentary STEVEN GROSSMAN 11/9/18 Just How Lame Is This Lame Duck Going to Be? Read More Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Will Congress Complete Appropriations in the Post-Recess Session or Further Extend the CR? Read More Analysis and Commentary STEVEN GROSSMAN 11/2/18 Analysis and Commentary STEVEN GROSSMAN 11/2/18 Changes Are Inevitable. Some Predictable; Others Not Read More Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Will Congress Complete Appropriations in the Post-Recess Session? Read More Analysis and Commentary STEVEN GROSSMAN 10/19/18 Analysis and Commentary STEVEN GROSSMAN 10/19/18 And While the Deputy Director is Still Away ... Read More Advocacy at a Glance STEVEN GROSSMAN 10/19/18 Advocacy at a Glance STEVEN GROSSMAN 10/19/18 Trump Threatens 5% Spending Cut for Agencies, $700B Pentagon Budget Read More Analysis and Commentary STEVEN GROSSMAN 10/12/18 Analysis and Commentary STEVEN GROSSMAN 10/12/18 In the Deputy Director's Absence ... Read More Analysis and Commentary STEVEN GROSSMAN 10/5/18 Analysis and Commentary STEVEN GROSSMAN 10/5/18 Will This Year’s Lame Duck Conduct “Business as Usual”? Read More Advocacy at a Glance STEVEN GROSSMAN 10/5/18 Advocacy at a Glance STEVEN GROSSMAN 10/5/18 October 1 Came and Went: CR Covers FDA Until December 7 Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 1/4/19 Analysis and Commentary STEVEN GROSSMAN 1/4/19 Can the Alliance Help to End the Shutdown? No and Yes! Read More
Advocacy at a Glance STEVEN GROSSMAN 1/4/19 Advocacy at a Glance STEVEN GROSSMAN 1/4/19 Soon To Be Released: Alliance’s FDA Shutdown Toolkit Read More
STEVEN GROSSMAN 12/21/18 STEVEN GROSSMAN 12/21/18 What Happens At and After Midnight, Cinderella? Read More
Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Advocacy at a Glance STEVEN GROSSMAN 12/21/18 Barring a Last-Minute Deal, A Partial FDA Shutdown is Likely Read More
Analysis and Commentary STEVEN GROSSMAN 12/15/18 Analysis and Commentary STEVEN GROSSMAN 12/15/18 Is a Shutdown on the Horizon? Read More
Analysis and Commentary STEVEN GROSSMAN 12/10/18 Analysis and Commentary STEVEN GROSSMAN 12/10/18 Critical Issues for the CVM Moving Forward Read More
Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Advocacy at a Glance STEVEN GROSSMAN 12/10/18 Two-Week CR Extension: Can It End the Impasse? Read More
Analysis and Commentary STEVEN GROSSMAN 11/30/18 Analysis and Commentary STEVEN GROSSMAN 11/30/18 "The Best of Times" ... "The Worst of Times" Read More
Advocacy at a Glance STEVEN GROSSMAN 11/30/18 Advocacy at a Glance STEVEN GROSSMAN 11/30/18 A Full Year Continuing Resolution: The Biggest Threat to FDA’s FY19 Funding Read More
Analysis and Commentary STEVEN GROSSMAN 11/20/18 Analysis and Commentary STEVEN GROSSMAN 11/20/18 Let Us All -- Again -- Give Thanks Read More
Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Advocacy at a Glance STEVEN GROSSMAN 11/20/18 Special Thanksgiving Message Read More
Analysis and Commentary STEVEN GROSSMAN 11/9/18 Analysis and Commentary STEVEN GROSSMAN 11/9/18 Just How Lame Is This Lame Duck Going to Be? Read More
Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Advocacy at a Glance STEVEN GROSSMAN 11/9/18 Will Congress Complete Appropriations in the Post-Recess Session or Further Extend the CR? Read More
Analysis and Commentary STEVEN GROSSMAN 11/2/18 Analysis and Commentary STEVEN GROSSMAN 11/2/18 Changes Are Inevitable. Some Predictable; Others Not Read More
Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Advocacy at a Glance STEVEN GROSSMAN 11/2/18 Will Congress Complete Appropriations in the Post-Recess Session? Read More
Analysis and Commentary STEVEN GROSSMAN 10/19/18 Analysis and Commentary STEVEN GROSSMAN 10/19/18 And While the Deputy Director is Still Away ... Read More
Advocacy at a Glance STEVEN GROSSMAN 10/19/18 Advocacy at a Glance STEVEN GROSSMAN 10/19/18 Trump Threatens 5% Spending Cut for Agencies, $700B Pentagon Budget Read More
Analysis and Commentary STEVEN GROSSMAN 10/12/18 Analysis and Commentary STEVEN GROSSMAN 10/12/18 In the Deputy Director's Absence ... Read More
Analysis and Commentary STEVEN GROSSMAN 10/5/18 Analysis and Commentary STEVEN GROSSMAN 10/5/18 Will This Year’s Lame Duck Conduct “Business as Usual”? Read More
Advocacy at a Glance STEVEN GROSSMAN 10/5/18 Advocacy at a Glance STEVEN GROSSMAN 10/5/18 October 1 Came and Went: CR Covers FDA Until December 7 Read More
